{"ticker": {"uuid": "2b54e02b-1441-43ca-8cf6-5798bc73166f", "symbol": "NKTR", "name": "Nektar Therapeutics", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178", "summary": "BTIG has reiterated its Buy rating for Nektar Therapeutics (NKTR.US) and maintained its price target of $178. This indicates the firm's continued confidence in the company's stock performance and future prospects.", "url": "https://news.futunn.com/en/post/75996871/btig-maintains-nektar-therapeutics-nktrus-with-buy-rating-maintains-target", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T21:13:50", "published_display": "14 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNaXVwNTZnNWVaS3pibHFEbnNjZWhvSGd2TUtpU2YyRERocTR1SWwwUWVkX3RiaVpobW5WYjR6S01VWEw2eTU0MERPQmpyU2FOaEYyY0VZWHhCSkxaeTNnV1hESnM3SG94YXRtXzBNd0k2d01HYmphSHQxdWQ5MVB1dTJJRW1sVXZaSzBCd3VGRGhsWjhGand2QU5ac19LSU5NbWpHYV9uRXRYekJFUF94OGZvUFVQbmNmNzZZWUJjc0czVnQtd2UxUzBQcENpczRHYUMzcm5lcFhhQQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-11T03:34:46+00:00", "published_display": "11 Jul 2026 03:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative?", "summary": "Nektar Therapeutics (NKTR) has been simultaneously added to both growth and value Russell indexes, indicating divergent market interpretations of its risk-reward profile. The company's future largely hinges on the success of its drug REZPEG, currently in Phase 3 trials, and its a", "url": "https://www.sahmcapital.com/news/content/does-nektar-therapeutics-nktr-straddling-russell-growth-and-value-indexes-reveal-a-conflicted-narrative-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T20:41:17", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. B", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180656", "source_name": "ACCESS Newswire", "published_at": "2026-07-10T07:09:29", "published_display": "10 Jul 2026 07:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR)", "summary": "Two healthcare companies, Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR), received bullish sentiments from analysts. H.C. Wainwright reiterated a Buy rating for Pyxis Oncology with a $7.00 price target, and for Nektar Therapeutics with a $185.00 price target, both implying ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PYXS-Q/pressreleases/3155275/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-nektar-therapeutics-nktr/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T18:39:54", "published_display": "07 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nektar Therapeutics \u2013 LSE:0UNL", "summary": "This article provides access to the enterprise value to EBITDA forward metric for Nektar Therapeutics (LSE:0UNL) on the TradingView platform. It highlights the availability of this financial data for the company listed on the London Stock Exchange, within the Health Technology se", "url": "https://www.tradingview.com/symbols/LSE-0UNL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T18:11:15", "published_display": "07 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?", "summary": "Nektar Therapeutics (NKTR) is gaining attention due to positive mid-stage data for its autoimmune pipeline, specifically in alopecia areata and upcoming late-stage trials in atopic dermatitis. Despite recent share price momentum, the stock's valuation, including a P/S ratio well ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the", "source_name": "Simply Wall Street", "published_at": "2026-07-06T06:09:50", "published_display": "06 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema", "summary": "Shares of Nektar Therapeutics (NKTR) surged 10% as investors anticipate upcoming clinical data for its lead drug, rezpegaldesleukin, aimed at autoimmune and inflammatory diseases. The company plans to initiate late-stage trials for atopic dermatitis by the end of July 2026 and ex", "url": "https://stocktwits.com/news-articles/markets/equity/nktr-stock-clocks-best-day-in-over-2-months-as-investors-await-upcoming-clinical-data-in-eczema/cZm97YVR7jf", "source_name": "Stocktwits", "published_at": "2026-07-04T17:10:45", "published_display": "04 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics (NKTR) R&D chief sells 5,681 shares under 10b5-1 plan", "summary": "Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 5,681 shares of common stock at $70.00 per share, totaling $397,670, on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 13, 2026. Following the sale, Zalev", "url": "https://www.stocktitan.net/sec-filings/NKTR/form-4-nektar-therapeutics-insider-trading-activity-d407d0e84242.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:39:54", "published_display": "03 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics updates its biotech strategy. Investors weigh the outlook for NKTR stock", "summary": "Nektar Therapeutics is refining its biotech strategy, focusing its clinical pipeline on immunology and oncology programs amid a challenging funding environment. The company is streamlining programs, prioritizing indications with clear development pathways, and emphasizing operati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/nektar-therapeutics-updates-its-biotech-strategy-investors-weigh-the/69680225", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T13:39:15", "published_display": "03 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nektar Therapeutics For: 2 July By Investing.com", "summary": "This article reports a Form 4 filing for Nektar Therapeutics (NKTR) on July 2. Form 4s disclose changes in beneficial ownership of securities by company insiders. The article includes the stock symbol NKTR and its performance data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-nektar-therapeutics-for-2-july-93CH-4719360", "source_name": "Investing.com Canada", "published_at": "2026-07-03T04:39:59", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics R&D chief sells $397,670 of common stock", "summary": "Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 5,681 shares of common stock for $397,670 on June 30, 2026, as per a Rule 10b5-1 trading plan. The stock has seen significant gains, but InvestingPro analysis suggests it might be overvalued. Nektar Therapeutics al", "url": "https://www.investing.com/news/insider-trading-news/nektar-therapeutics-rd-chief-sells-397670-of-common-stock-93CH-4774710", "source_name": "Investing.com", "published_at": "2026-07-03T00:10:25", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves", "summary": "Nektar Therapeutics (NKTR) stock surged due to positive trial data and optimism surrounding partnerships, particularly after Canaccord cited the company as a beneficiary of AbbVie's acquisition of Apogee Therapeutics. The company is actively hiring and aligning talent with its fo", "url": "https://www.timothysykes.com/news/nektar-therapeutics-nktr-news-2026_07_02/", "source_name": "Timothy Sykes", "published_at": "2026-07-02T21:10:25", "published_display": "02 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Nektar Therapeutics\u2019 Broad FTSE Russell Index Inclusion Will Impact Nektar Therapeutics (NKTR) Investors", "summary": "Nektar Therapeutics (NKTR) has been included in several FTSE Russell indices, including the Russell 2000, 2500, and 3000, which is expected to increase its visibility and trading liquidity. While this broad index inclusion doesn't change the company's fundamental challenges, it m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/how-nektar-therapeutics-broad-ftse-russell-index-inclusion-w/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-02T11:10:25", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them to participate in the investi", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180653", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to contact them for more in", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-nektar-therapeutic-1180652", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T16:10:17", "published_display": "01 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jonathan Zalevsky (NKTR) sells 5,737 shares via 10b5-1 plan", "summary": "Jonathan Zalevsky, an individual associated with NEKTAR THERAPEUTICS (NKTR), has reported the sale of 5,737 shares of common stock through a pre-arranged 10b5-1 plan. The sales occurred in two transactions: 199 shares on May 19, 2026, for $13,036.49, and 5,538 shares on June 15, ", "url": "https://www.stocktitan.net/sec-filings/NKTR/144-nektar-therapeutics-sec-filing-8c193fe6d080.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:38:59", "published_display": "01 Jul 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Value Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 2000 Value Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with its lead product candidate rezpegaldesl", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-2000-value-benchmark-ce7f5fded18ef123", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:27", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Growth Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR) has been added to the Russell 2000 Growth Benchmark. The company is a clinical-stage biotechnology firm focused on developing treatments for autoimmune, chronic inflammatory diseases, and cancer, with lead product candidate rezpegaldesleukin u", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-2000-growth-benchmark-ce7f5fdedc8ff526", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:41:27", "published_display": "29 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Growth Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 3000E Growth Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with lead product candidate rezpegaldesleu", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-3000e-growth-benchmark-ce7f5fdedb8eff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:37", "published_display": "29 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Actuals & Estimates (NASDAQ:NKTR)", "summary": "This article provides an overview of Nektar Therapeutics (NASDAQ:NKTR) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial actuals, upcoming earnings dates, and past earnings and revenue figures. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T11:11:00", "published_display": "28 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nektar Therapeutics \u2013 SWB:ITH0", "summary": "This article from TradingView provides financial information for Nektar Therapeutics (SWB:ITH0), specifically focusing on its \"Price to sales forward\" metric. The content appears to be a stub or a section of a larger financial data page, showing the financial metric, period, valu", "url": "https://www.tradingview.com/symbols/SWB-ITH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:11:00", "published_display": "28 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPeEROd2JSTHVPOU9ya3QxYzBlaG55eDhZOVhSaTlXYmwzdjRoX3FHQWVBSTFfSGVWMTBzXzdwMjN2V0R3U21IU2Jfd1FvdE5FV2VCTDNYWndtakdhVlVobFRjRVBlMmlHUko1NlpLUFdiR2t2b2pJVWp5VDhQRnd3TEVnRUtBRnZQckdsV2R2RzJJMGRkbEw1RzVhd3FhOWJQcVRrakgxdTJVc3lnaTRIZmRNU1hCZkVhV3pWY1A2cTd0QjNhNmYwXzAyc2d1bkc2bXhLQ2ZR?oc=5", "source_name": "Morningstar", "published_at": "2026-06-26T20:30:00+00:00", "published_display": "26 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nektar Therapeutics \u2013 DUS:ITH0", "summary": "This article provides an overview of Nektar Therapeutics (DUS:ITH0) on the Dusseldorf Stock Exchange, focusing on its financials, specifically the \"Price to sales forward\" metric. The content highlights that the market is currently closed with no trades. It also details the vario", "url": "https://www.tradingview.com/symbols/DUS-ITH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:34", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nektar Therapeutics \u2013 NASDAQ:NKTR", "summary": "This article provides financial information for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its forward price-to-earnings ratio. It is a data-oriented page from TradingView, presenting a quantitative financial metric without editorial commentary. The content feat", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:41", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nektar Therapeutics \u2013 DUS:ITH0", "summary": "This article provides financial information for Nektar Therapeutics (DUS:ITH0), specifically focusing on its Enterprise Value to EBITDA forward metric. It displays a table showing the period, value, change, and percentage change for this financial indicator. The page appears to b", "url": "https://www.tradingview.com/symbols/DUS-ITH0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:17", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar awards stock to 7 new hires under inducement plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcC10dFhaQ1I1ZlhtQ3ZGRXVxUXk2dnAwTDRkWUc5Z0xGeFZCV0Y1UmlHSElFWDhzWGtsVkhEZnkxUzQ5eUVPdWQ5MGlqMGtfZDBmVXVpX2dQU2hDbmg4WHRFLTlwY0Y2bDU2Y2pWVFA4aFRxcFEwSXZXamJDcS1oM2lLSUREU2lFRXRtd2kyaldNWTZFRGZuLXNVaFpuZy1zNDQyZ1VHdVBDT3lQWDFpbUotTDI3RF9FVFFaQnlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Nektar Therapeutics (NKTR) stock, including analyst price targets, historical performance, and key financial metrics. Analysts have a maximum price target of $192.00 and a minimum of $80.00 for NKTR. The company's stock has seen significant gr", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:09:43", "published_display": "25 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year", "summary": "", "url": "https://finance.yahoo.com/m/a31ecd8e-0e4e-3b15-ae47-ab817ee69b79/what-a-%241.2-million-insider.html", "source_name": "Motley Fool", "published_at": "2026-06-24T19:59:19+00:00", "published_display": "24 Jun 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Nektar Therapeutics (NASDAQ:NKTR) for potential corporate wrongdoing. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to connect to assist in the investigation. The", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-nektar-thera-1180649", "source_name": "ACCESS Newswire", "published_at": "2026-06-24T01:12:50", "published_display": "24 Jun 2026 01:12", "sentiment": "negative", "sentiment_pct": 11, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics chief R&D officer sells $336,211 in stock", "summary": "Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, recently sold 5,538 shares of the company's common stock for $336,211 through a Rule 10b5-1 trading plan. This insider sale follows a significant 617% surge in NKTR shares over the past year. The company is also making ", "url": "https://m.uk.investing.com/news/stock-market-news/nektar-therapeutics-chief-rd-officer-sells-336211-in-stock-93CH-4738580?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T05:12:48", "published_display": "23 Jun 2026 05:12", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Insider Sold Shares Worth $1,215,056, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nektar-therapeutics-insider-sold-shares-080953161.html", "source_name": "MT Newswires", "published_at": "2026-06-22T08:09:53+00:00", "published_display": "22 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] NEKTAR THERAPEUTICS SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQWVZjN0h5OGpDNkdUR0NmSkdCenoweUpKNXFqOUtLVHd2aTkza1ZmamxObHB0bjlTdU5qUnh5Y2FsSGhmckxNdEVvRUhDNnJHbVNEbUs2R0w1U3VQejlzUnk0WXkydFp0dTFmal8tbHE2ck95YW5xcGMwWHpidGVGeEFVRGplWFExa1VZQnBkX3pkc0Vwd2xVOEpPbDc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/look-nektar-therapeutics-nktr-valuation-031023243.html", "source_name": "Simply Wall St.", "published_at": "2026-06-07T03:10:23+00:00", "published_display": "07 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNb2U0RFU3YXZINUFrZG5ubjZMYklRVWZmRjZ4c2pUV2xteTFlVjVfMTBBbnVuaENuUEg4R3VxTk9sbkE1U2tTdDZ5TUw1QXN6eXNEVkM1VEExLTctSURYTDBIekRyWlhWMHRBc0NFUzFkcHkxQkg2YzlYU2tKSEZiT05ZUTJpQVhCOGtiSW9ucHFHaXBOM2c1RnE2MHAtaXU5NHBEV09NS0VuZDQ2clE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nektar-therapeutics-participate-2026-jefferies-220000417.html", "source_name": "PR Newswire", "published_at": "2026-05-27T22:00:00+00:00", "published_display": "27 May 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch", "summary": "", "url": "https://finance.yahoo.com/m/984cbe7d-52de-33bf-9c13-c03c9bbf4c80/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-05-23T20:48:41+00:00", "published_display": "23 May 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar Therapeutics stock (US6354171056): $400M capital raise fuels Phase 3 autoimmune pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNdE9pTkFlbE5qVnp5SE5MN3RpZ2VheVhteDBYVWRFNkF6TFp6Xy1zSEJVWUxjNzVCVEN1NkVaa1Q1aTljYjNyZ0VLcWpJRjViM0Z1eHNLd19ZQjdpXzdER1ZMejlxY1pCRHBUNHNTc2tfSkhxZEU0ZEJQdkd4X1VyM1QzSzR3TUsteFN4bU81LVpNRzNacmsxakhSV0IwZFlESU1ObEExSkhnMWt4UVhqZG03cndXMEpFbm5pQ3Q0M2ZzU1Z2MWdj?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMi1lRFNqTWVORjJCSmY1QlFPcUJLelRVY2JGaFVlZDI2THA3ekZJUlc5cEFBXzVIUnJwMDVlbVJiVU5tWHpPVVhtS1hlTE5nM2Y1WHBkUXVDT0hFTnVUMEkyZW9mWjBOYmFiQ25qR3ViUVI2WUY5eEFhZXpqQnE2eHpyS25IXy1hVDdWUVNHOFVDY1Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPcmpfaHAtdnRtMzlPVXBvbktDdndVeVFhdDhiNEZ5bmdBOHZmeHgxMktjNWxUSmdqc09lUmtwZkFscXFGeE5xdzZ2QjlFaGZVNTVzV3VGR2QtRXdWOUExVVg2RGVVaTdKTXhJSFF1RUt6Q2RXTHZHSnRDRU1lTjJTRWxKYWNIU01LWkxDUnl3YjFIc0JJUXVXZzdmNXlmNzVBalQySURrYzBqTlA3dWQ2eURjU1d6amx1YUM0SnRxVzUzRndlWFRPY3VfYXJmM2hvLTNEVjF5VUZ0cVczeU9iVklCVUNuT03SAewBQVVfeXFMUFRHZVRwMHdsbnlraVNxWkltZkUtNWpJTzBZdzZ3NGFaQWJyblM3YnEzZExjZlIzYjdhUHQyX01maFF3b090ZVFLMjNDWm9xNVc5SjlDWUN0empxckVQcFNpXzhXNk82bEcxYlZNbjhlYWVkeU5pdGc5RmhCcWRzV0gwVG9NTUQtRk5IUW5HMjNNUjJsdTdDTVp1V2JhMVdjNzhnQ3VIQ2pSWGNlX0NpcTNWOUl3S0NSWHR4V1hvN3JHeGpMMEhUb0NocHBQMVRCcWZ6VUkzRFNlc2RJbHd6dndkYld3ZTQzQUVQZ2I?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSDlBMThOblhhdDQ0TjRJRlVmeW1vT0hkcm9sbWd0MTlLWlJYY1hobjBQNkpRa2otWUZUSTFTWVlqRE95bnBqcUdzdDE2RE43aVhPTTRCZ2ZyaGwtY3BSZDBQdHVBVUN1ZS13RWVuQ2o1UkVVNFZRVDlzeUE4ZXZSZ01hU29TUzJvU0xQVnJkcjh4SF9SbG9FV0lJSGhjWFR4X0U3dF82VmVqWnE2MDNibmhOWGI2YXpXSjNoTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNEU3bHYyd2Y5MHdnS0VRaVVQM3lxWjRZT1A5OXlvOExTWFNuaFlWd09ERGw4OTI4bHYzSUFDNUxoSko3RkR2YUpCOHBEUzg4clAwR1pwRVg5NnliQVVMVUhMTVFOUG9TSE1UbzNhUFh4cVBaYUF5T2ctdm5GdElMMm5pZ2c2TkNNTVhwR0VxLXdtMDRaUFpUQjZGY3FyV0daQ0tyQmpQdUpURXFGRl9sWU1vamZjY2JjcWJJbQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMUlaTmV1QWlKSjZwamRmRDdyTlNtUnJ3VnJhUldkRUNyOEZ1ZGZwRGYydG14MDZsRXN0bWZxVVV4cjFKdUh2aDlleklIekViaVpfRnM5U1dId05WWEY5ZkR6VDhhOVNJdVIwS3hWeDV5NlJGX0NNeEk0WEFCd0RNclBZeWp1SEJiSkRtYzFlZzcwTVgxdE92RXhwTGdKYUdrcFpuN2VXWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxPRGJ5WHNWU0lBSkNDRFNqQzlyU3JXZmRXNVd5UVVsRmRJMDBnN3lGQW91NWttZEcyNDBjb0xXODY0TE9CczNaLXNxNEM5bmRkM3IycTI5dWtkQzVWcmRIbFNuNmthbXg2aC1IcmVZbkxfT0pDaDNyN25GU3pYRWRveVJ1cTNpYVVDbVNCdkFoVVRDNUUtOWlJbW8tZWNiYW1HRnFpMkMtUlJ4aUJ2WUxZck5LeWN6bURhYWtXZWdlWmtvOGN1emt3MGtlOEZvZDNpR0JtNEcyeG4zMmJpbDFWYUQ4RVQxczNqbVV5YmdVWThKbGsyeHRpYVBlMnluT21faXFmdHFJMWdFcFd6ZTFJZjE5U2ZKWFcxTFRnRHBoaTJMaUU2LU8tYmxlTQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Clinical Data for Hair Loss Treatment Drives Nektar Therapeutics Stock to Surge in a Single Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZm81akg5dVN3Rnc1Zk1DTF81bldoX0x0b0ZtOEUxQ21TUjUxU3BCU19UYVJseUlyc2p3eFoxNnpVMmExT0tMWHVnenNsZFRCWjlUSmxKa1hEYlMwZ0lvZTFaU1JwVFE4V0lzS3BORVRNVWpNQkUyRVNUaTRBTmZtdUwtOWM2MHc5Tk9GbFY4VjdkUmpkYjhSaE1oNi0wOVFKdXk5cHhiZnlHUVFlQzNXU0pTYmQ1QzhROXFrVWZUUGdfUEpLSEZFUm5aWnFSNG1GUWEw?oc=5", "source_name": "NAI500", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQV2VFb19PMmZaQ3pLM2l0MXd6MkVSVUI2eGZzZXlHYVF1WDRNc3d3bTNOZm90SE5XUDhONXE4QmlydDd6UGE3QlgwSkQ1aFRhYm5XUjlJbmk1MUVwTXRjZ3QzTUVHekJjRERFc1JMZFlCNXVjc0ZoVHVkMkh5YWNfNFljU0M5QVZqS2J5ZVVZbG0?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar Therapeutics Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOGdCZjRkZjBoRkFxa3RYNWp0MGNPTUdNZ0t1dF9pd1dyejZWTE4wX2hadHhJSzJ1QjJzVXljdEVHVk1SNDFnMGJHeWdDZlR0ZS1YbUc3WjRUX2tRcHVnOElLakNXYlFydTUyMlZxNVRuRl9COGQ1OWhJNEFTRzJiZElfUnlTTjZyS0x5cXFSUjRnZ1NjSVpCT003dU1jdjB0b3lReFZZczh3RFVYcEVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQb004VVV0MmJjZUNRUzdiX2RGS2FQUC1nVHlvRkNXSEo1LTRESmZkSWVQbHJZOVpBMG5DNE5NU0ZCaGR1UkQ2cXFIT2RSNGd5RzQwUTJnS045UU1iUThKeEk0dDQ2WGl4U1UtbGFWSnBMY2J4WE5CaVFrOGl6Rms2M2dSUEhHVUFuZjlsZ19iNFA0WHJHdUYzZjhWRk1xTkxBZVZrZmtSSFVBMDZt?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar raises $460M ahead of Phase 3 atopic dermatitis trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQWtHeFVkaExEdWxsZU9RQVhjVDFSQnZwY29tMjdZWXdpaVM0T3VtLWdiTFQwcnZJTHhmU0d2OXNTUVFwRWZCMmNjWkNtUnFSaUgzVGlYRnVsQnlnZnlRNkIzY3doRzd4enZSNHZZUzJSTnJDZXA1b18yX0pvMFQ0YXB2NjVFa0ZCel9QOVZCSHJsb25Ub1VrOXdkOWtENE9uNHhhVE8yQTZrX1FiNjBkak0zTkQyLXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQZ3VmZUpLOHVoSEZncXdna0pfazdzNTIxRGd2dFZJZ3RXNWY3N3ZwUzlYdGNxTW55SjhiaEZZOUw2RnNIc3NnQ2ZOdm9IMkRkSURxb1d2cVlpV19rLWhyd2tzWHVrVjNXTng2d3B0NmZiOUZfTUtCZDFxVjY5TW5iaGh2REtpQUtfbFluNHVHQ2U0cWkzaEFtQW5tZlc4ck96UmY5TEVnVHFSSlJMNE50ZlZkcnFweUt3SVNyY2Vhc3BsUExZUHRLOEdicW9jMDgx?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxOemROUE41bjFzLVdlOGVTMEdtVm96NU92R3RxVk5XNl9BcEg0VndycDhOR2xZeHUzc2lPUU92WHJkQVkyaUgwcmRYUDk0dFMwZnZJRE1QNHpuSEZrYzNOQmlWMXBneFFWX004dU9qVGF2Ymc3Z3QtLXpBR1U5T19WN1JITnY4YjhNLVB4S3B3cExQS19IZHNLdVZDcDRoTkxiWVVyUU1DTzBMYzJOeUwyZGFkTTU3VVFHUWprd1ViUVRqd3VfbEdKcGJiQW05Tm9SMVdhN1pBN01rUy1FWVpQWnNsNlZ3ejJjZURtd0IzcVJ3aHFqcjJILVM4RXE4cjR4QnEzdHZMODZHTThJcXlFR3Bpcw?oc=5", "source_name": "BioSpace", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178", "summary": "BTIG has reiterated its Buy rating for Nektar Therapeutics (NKTR.US) and maintained its price target of $178. This indicates the firm's continued confidence in the company's stock performance and future prospects.", "url": "https://news.futunn.com/en/post/75996871/btig-maintains-nektar-therapeutics-nktrus-with-buy-rating-maintains-target", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T21:13:50", "published_display": "14 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNaXVwNTZnNWVaS3pibHFEbnNjZWhvSGd2TUtpU2YyRERocTR1SWwwUWVkX3RiaVpobW5WYjR6S01VWEw2eTU0MERPQmpyU2FOaEYyY0VZWHhCSkxaeTNnV1hESnM3SG94YXRtXzBNd0k2d01HYmphSHQxdWQ5MVB1dTJJRW1sVXZaSzBCd3VGRGhsWjhGand2QU5ac19LSU5NbWpHYV9uRXRYekJFUF94OGZvUFVQbmNmNzZZWUJjc0czVnQtd2UxUzBQcENpczRHYUMzcm5lcFhhQQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-11T03:34:46+00:00", "published_display": "11 Jul 2026 03:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative?", "summary": "Nektar Therapeutics (NKTR) has been simultaneously added to both growth and value Russell indexes, indicating divergent market interpretations of its risk-reward profile. The company's future largely hinges on the success of its drug REZPEG, currently in Phase 3 trials, and its a", "url": "https://www.sahmcapital.com/news/content/does-nektar-therapeutics-nktr-straddling-russell-growth-and-value-indexes-reveal-a-conflicted-narrative-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T20:41:17", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. B", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180656", "source_name": "ACCESS Newswire", "published_at": "2026-07-10T07:09:29", "published_display": "10 Jul 2026 07:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR)", "summary": "Two healthcare companies, Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR), received bullish sentiments from analysts. H.C. Wainwright reiterated a Buy rating for Pyxis Oncology with a $7.00 price target, and for Nektar Therapeutics with a $185.00 price target, both implying ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PYXS-Q/pressreleases/3155275/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-nektar-therapeutics-nktr/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T18:39:54", "published_display": "07 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nektar Therapeutics \u2013 LSE:0UNL", "summary": "This article provides access to the enterprise value to EBITDA forward metric for Nektar Therapeutics (LSE:0UNL) on the TradingView platform. It highlights the availability of this financial data for the company listed on the London Stock Exchange, within the Health Technology se", "url": "https://www.tradingview.com/symbols/LSE-0UNL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T18:11:15", "published_display": "07 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?", "summary": "Nektar Therapeutics (NKTR) is gaining attention due to positive mid-stage data for its autoimmune pipeline, specifically in alopecia areata and upcoming late-stage trials in atopic dermatitis. Despite recent share price momentum, the stock's valuation, including a P/S ratio well ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the", "source_name": "Simply Wall Street", "published_at": "2026-07-06T06:09:50", "published_display": "06 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema", "summary": "Shares of Nektar Therapeutics (NKTR) surged 10% as investors anticipate upcoming clinical data for its lead drug, rezpegaldesleukin, aimed at autoimmune and inflammatory diseases. The company plans to initiate late-stage trials for atopic dermatitis by the end of July 2026 and ex", "url": "https://stocktwits.com/news-articles/markets/equity/nktr-stock-clocks-best-day-in-over-2-months-as-investors-await-upcoming-clinical-data-in-eczema/cZm97YVR7jf", "source_name": "Stocktwits", "published_at": "2026-07-04T17:10:45", "published_display": "04 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics (NKTR) R&D chief sells 5,681 shares under 10b5-1 plan", "summary": "Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 5,681 shares of common stock at $70.00 per share, totaling $397,670, on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 13, 2026. Following the sale, Zalev", "url": "https://www.stocktitan.net/sec-filings/NKTR/form-4-nektar-therapeutics-insider-trading-activity-d407d0e84242.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:39:54", "published_display": "03 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics updates its biotech strategy. Investors weigh the outlook for NKTR stock", "summary": "Nektar Therapeutics is refining its biotech strategy, focusing its clinical pipeline on immunology and oncology programs amid a challenging funding environment. The company is streamlining programs, prioritizing indications with clear development pathways, and emphasizing operati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/nektar-therapeutics-updates-its-biotech-strategy-investors-weigh-the/69680225", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T13:39:15", "published_display": "03 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nektar Therapeutics For: 2 July By Investing.com", "summary": "This article reports a Form 4 filing for Nektar Therapeutics (NKTR) on July 2. Form 4s disclose changes in beneficial ownership of securities by company insiders. The article includes the stock symbol NKTR and its performance data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-nektar-therapeutics-for-2-july-93CH-4719360", "source_name": "Investing.com Canada", "published_at": "2026-07-03T04:39:59", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics R&D chief sells $397,670 of common stock", "summary": "Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 5,681 shares of common stock for $397,670 on June 30, 2026, as per a Rule 10b5-1 trading plan. The stock has seen significant gains, but InvestingPro analysis suggests it might be overvalued. Nektar Therapeutics al", "url": "https://www.investing.com/news/insider-trading-news/nektar-therapeutics-rd-chief-sells-397670-of-common-stock-93CH-4774710", "source_name": "Investing.com", "published_at": "2026-07-03T00:10:25", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves", "summary": "Nektar Therapeutics (NKTR) stock surged due to positive trial data and optimism surrounding partnerships, particularly after Canaccord cited the company as a beneficiary of AbbVie's acquisition of Apogee Therapeutics. The company is actively hiring and aligning talent with its fo", "url": "https://www.timothysykes.com/news/nektar-therapeutics-nktr-news-2026_07_02/", "source_name": "Timothy Sykes", "published_at": "2026-07-02T21:10:25", "published_display": "02 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Nektar Therapeutics\u2019 Broad FTSE Russell Index Inclusion Will Impact Nektar Therapeutics (NKTR) Investors", "summary": "Nektar Therapeutics (NKTR) has been included in several FTSE Russell indices, including the Russell 2000, 2500, and 3000, which is expected to increase its visibility and trading liquidity. While this broad index inclusion doesn't change the company's fundamental challenges, it m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/how-nektar-therapeutics-broad-ftse-russell-index-inclusion-w/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-02T11:10:25", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them to participate in the investi", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180653", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to contact them for more in", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-nektar-therapeutic-1180652", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T16:10:17", "published_display": "01 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jonathan Zalevsky (NKTR) sells 5,737 shares via 10b5-1 plan", "summary": "Jonathan Zalevsky, an individual associated with NEKTAR THERAPEUTICS (NKTR), has reported the sale of 5,737 shares of common stock through a pre-arranged 10b5-1 plan. The sales occurred in two transactions: 199 shares on May 19, 2026, for $13,036.49, and 5,538 shares on June 15, ", "url": "https://www.stocktitan.net/sec-filings/NKTR/144-nektar-therapeutics-sec-filing-8c193fe6d080.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:38:59", "published_display": "01 Jul 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Value Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 2000 Value Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with its lead product candidate rezpegaldesl", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-2000-value-benchmark-ce7f5fded18ef123", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:27", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Growth Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR) has been added to the Russell 2000 Growth Benchmark. The company is a clinical-stage biotechnology firm focused on developing treatments for autoimmune, chronic inflammatory diseases, and cancer, with lead product candidate rezpegaldesleukin u", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-2000-growth-benchmark-ce7f5fdedc8ff526", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:41:27", "published_display": "29 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Growth Benchmark", "summary": "Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 3000E Growth Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with lead product candidate rezpegaldesleu", "url": "https://www.marketscreener.com/news/nektar-therapeutics-nasdaqcm-nktr-added-to-russell-3000e-growth-benchmark-ce7f5fdedb8eff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:37", "published_display": "29 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Actuals & Estimates (NASDAQ:NKTR)", "summary": "This article provides an overview of Nektar Therapeutics (NASDAQ:NKTR) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial actuals, upcoming earnings dates, and past earnings and revenue figures. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T11:11:00", "published_display": "28 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nektar Therapeutics \u2013 SWB:ITH0", "summary": "This article from TradingView provides financial information for Nektar Therapeutics (SWB:ITH0), specifically focusing on its \"Price to sales forward\" metric. The content appears to be a stub or a section of a larger financial data page, showing the financial metric, period, valu", "url": "https://www.tradingview.com/symbols/SWB-ITH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:11:00", "published_display": "28 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPeEROd2JSTHVPOU9ya3QxYzBlaG55eDhZOVhSaTlXYmwzdjRoX3FHQWVBSTFfSGVWMTBzXzdwMjN2V0R3U21IU2Jfd1FvdE5FV2VCTDNYWndtakdhVlVobFRjRVBlMmlHUko1NlpLUFdiR2t2b2pJVWp5VDhQRnd3TEVnRUtBRnZQckdsV2R2RzJJMGRkbEw1RzVhd3FhOWJQcVRrakgxdTJVc3lnaTRIZmRNU1hCZkVhV3pWY1A2cTd0QjNhNmYwXzAyc2d1bkc2bXhLQ2ZR?oc=5", "source_name": "Morningstar", "published_at": "2026-06-26T20:30:00+00:00", "published_display": "26 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nektar Therapeutics \u2013 DUS:ITH0", "summary": "This article provides an overview of Nektar Therapeutics (DUS:ITH0) on the Dusseldorf Stock Exchange, focusing on its financials, specifically the \"Price to sales forward\" metric. The content highlights that the market is currently closed with no trades. It also details the vario", "url": "https://www.tradingview.com/symbols/DUS-ITH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:34", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nektar Therapeutics \u2013 NASDAQ:NKTR", "summary": "This article provides financial information for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its forward price-to-earnings ratio. It is a data-oriented page from TradingView, presenting a quantitative financial metric without editorial commentary. The content feat", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:41", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nektar Therapeutics \u2013 DUS:ITH0", "summary": "This article provides financial information for Nektar Therapeutics (DUS:ITH0), specifically focusing on its Enterprise Value to EBITDA forward metric. It displays a table showing the period, value, change, and percentage change for this financial indicator. The page appears to b", "url": "https://www.tradingview.com/symbols/DUS-ITH0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:17", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar awards stock to 7 new hires under inducement plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcC10dFhaQ1I1ZlhtQ3ZGRXVxUXk2dnAwTDRkWUc5Z0xGeFZCV0Y1UmlHSElFWDhzWGtsVkhEZnkxUzQ5eUVPdWQ5MGlqMGtfZDBmVXVpX2dQU2hDbmg4WHRFLTlwY0Y2bDU2Y2pWVFA4aFRxcFEwSXZXamJDcS1oM2lLSUREU2lFRXRtd2kyaldNWTZFRGZuLXNVaFpuZy1zNDQyZ1VHdVBDT3lQWDFpbUotTDI3RF9FVFFaQnlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Nektar Therapeutics (NKTR) stock, including analyst price targets, historical performance, and key financial metrics. Analysts have a maximum price target of $192.00 and a minimum of $80.00 for NKTR. The company's stock has seen significant gr", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:09:43", "published_display": "25 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year", "summary": "", "url": "https://finance.yahoo.com/m/a31ecd8e-0e4e-3b15-ae47-ab817ee69b79/what-a-%241.2-million-insider.html", "source_name": "Motley Fool", "published_at": "2026-06-24T19:59:19+00:00", "published_display": "24 Jun 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Nektar Therapeutics (NASDAQ:NKTR) for potential corporate wrongdoing. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to connect to assist in the investigation. The", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-nektar-thera-1180649", "source_name": "ACCESS Newswire", "published_at": "2026-06-24T01:12:50", "published_display": "24 Jun 2026 01:12", "sentiment": "negative", "sentiment_pct": 11, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics chief R&D officer sells $336,211 in stock", "summary": "Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, recently sold 5,538 shares of the company's common stock for $336,211 through a Rule 10b5-1 trading plan. This insider sale follows a significant 617% surge in NKTR shares over the past year. The company is also making ", "url": "https://m.uk.investing.com/news/stock-market-news/nektar-therapeutics-chief-rd-officer-sells-336211-in-stock-93CH-4738580?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T05:12:48", "published_display": "23 Jun 2026 05:12", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Insider Sold Shares Worth $1,215,056, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nektar-therapeutics-insider-sold-shares-080953161.html", "source_name": "MT Newswires", "published_at": "2026-06-22T08:09:53+00:00", "published_display": "22 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] NEKTAR THERAPEUTICS SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQWVZjN0h5OGpDNkdUR0NmSkdCenoweUpKNXFqOUtLVHd2aTkza1ZmamxObHB0bjlTdU5qUnh5Y2FsSGhmckxNdEVvRUhDNnJHbVNEbUs2R0w1U3VQejlzUnk0WXkydFp0dTFmal8tbHE2ck95YW5xcGMwWHpidGVGeEFVRGplWFExa1VZQnBkX3pkc0Vwd2xVOEpPbDc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/look-nektar-therapeutics-nktr-valuation-031023243.html", "source_name": "Simply Wall St.", "published_at": "2026-06-07T03:10:23+00:00", "published_display": "07 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNb2U0RFU3YXZINUFrZG5ubjZMYklRVWZmRjZ4c2pUV2xteTFlVjVfMTBBbnVuaENuUEg4R3VxTk9sbkE1U2tTdDZ5TUw1QXN6eXNEVkM1VEExLTctSURYTDBIekRyWlhWMHRBc0NFUzFkcHkxQkg2YzlYU2tKSEZiT05ZUTJpQVhCOGtiSW9ucHFHaXBOM2c1RnE2MHAtaXU5NHBEV09NS0VuZDQ2clE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nektar-therapeutics-participate-2026-jefferies-220000417.html", "source_name": "PR Newswire", "published_at": "2026-05-27T22:00:00+00:00", "published_display": "27 May 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch", "summary": "", "url": "https://finance.yahoo.com/m/984cbe7d-52de-33bf-9c13-c03c9bbf4c80/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-05-23T20:48:41+00:00", "published_display": "23 May 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics stock (US6354171056): $400M capital raise fuels Phase 3 autoimmune pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNdE9pTkFlbE5qVnp5SE5MN3RpZ2VheVhteDBYVWRFNkF6TFp6Xy1zSEJVWUxjNzVCVEN1NkVaa1Q1aTljYjNyZ0VLcWpJRjViM0Z1eHNLd19ZQjdpXzdER1ZMejlxY1pCRHBUNHNTc2tfSkhxZEU0ZEJQdkd4X1VyM1QzSzR3TUsteFN4bU81LVpNRzNacmsxakhSV0IwZFlESU1ObEExSkhnMWt4UVhqZG03cndXMEpFbm5pQ3Q0M2ZzU1Z2MWdj?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMi1lRFNqTWVORjJCSmY1QlFPcUJLelRVY2JGaFVlZDI2THA3ekZJUlc5cEFBXzVIUnJwMDVlbVJiVU5tWHpPVVhtS1hlTE5nM2Y1WHBkUXVDT0hFTnVUMEkyZW9mWjBOYmFiQ25qR3ViUVI2WUY5eEFhZXpqQnE2eHpyS25IXy1hVDdWUVNHOFVDY1Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSDlBMThOblhhdDQ0TjRJRlVmeW1vT0hkcm9sbWd0MTlLWlJYY1hobjBQNkpRa2otWUZUSTFTWVlqRE95bnBqcUdzdDE2RE43aVhPTTRCZ2ZyaGwtY3BSZDBQdHVBVUN1ZS13RWVuQ2o1UkVVNFZRVDlzeUE4ZXZSZ01hU29TUzJvU0xQVnJkcjh4SF9SbG9FV0lJSGhjWFR4X0U3dF82VmVqWnE2MDNibmhOWGI2YXpXSjNoTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNEU3bHYyd2Y5MHdnS0VRaVVQM3lxWjRZT1A5OXlvOExTWFNuaFlWd09ERGw4OTI4bHYzSUFDNUxoSko3RkR2YUpCOHBEUzg4clAwR1pwRVg5NnliQVVMVUhMTVFOUG9TSE1UbzNhUFh4cVBaYUF5T2ctdm5GdElMMm5pZ2c2TkNNTVhwR0VxLXdtMDRaUFpUQjZGY3FyV0daQ0tyQmpQdUpURXFGRl9sWU1vamZjY2JjcWJJbQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMUlaTmV1QWlKSjZwamRmRDdyTlNtUnJ3VnJhUldkRUNyOEZ1ZGZwRGYydG14MDZsRXN0bWZxVVV4cjFKdUh2aDlleklIekViaVpfRnM5U1dId05WWEY5ZkR6VDhhOVNJdVIwS3hWeDV5NlJGX0NNeEk0WEFCd0RNclBZeWp1SEJiSkRtYzFlZzcwTVgxdE92RXhwTGdKYUdrcFpuN2VXWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxPRGJ5WHNWU0lBSkNDRFNqQzlyU3JXZmRXNVd5UVVsRmRJMDBnN3lGQW91NWttZEcyNDBjb0xXODY0TE9CczNaLXNxNEM5bmRkM3IycTI5dWtkQzVWcmRIbFNuNmthbXg2aC1IcmVZbkxfT0pDaDNyN25GU3pYRWRveVJ1cTNpYVVDbVNCdkFoVVRDNUUtOWlJbW8tZWNiYW1HRnFpMkMtUlJ4aUJ2WUxZck5LeWN6bURhYWtXZWdlWmtvOGN1emt3MGtlOEZvZDNpR0JtNEcyeG4zMmJpbDFWYUQ4RVQxczNqbVV5YmdVWThKbGsyeHRpYVBlMnluT21faXFmdHFJMWdFcFd6ZTFJZjE5U2ZKWFcxTFRnRHBoaTJMaUU2LU8tYmxlTQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Clinical Data for Hair Loss Treatment Drives Nektar Therapeutics Stock to Surge in a Single Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZm81akg5dVN3Rnc1Zk1DTF81bldoX0x0b0ZtOEUxQ21TUjUxU3BCU19UYVJseUlyc2p3eFoxNnpVMmExT0tMWHVnenNsZFRCWjlUSmxKa1hEYlMwZ0lvZTFaU1JwVFE4V0lzS3BORVRNVWpNQkUyRVNUaTRBTmZtdUwtOWM2MHc5Tk9GbFY4VjdkUmpkYjhSaE1oNi0wOVFKdXk5cHhiZnlHUVFlQzNXU0pTYmQ1QzhROXFrVWZUUGdfUEpLSEZFUm5aWnFSNG1GUWEw?oc=5", "source_name": "NAI500", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQV2VFb19PMmZaQ3pLM2l0MXd6MkVSVUI2eGZzZXlHYVF1WDRNc3d3bTNOZm90SE5XUDhONXE4QmlydDd6UGE3QlgwSkQ1aFRhYm5XUjlJbmk1MUVwTXRjZ3QzTUVHekJjRERFc1JMZFlCNXVjc0ZoVHVkMkh5YWNfNFljU0M5QVZqS2J5ZVVZbG0?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOGdCZjRkZjBoRkFxa3RYNWp0MGNPTUdNZ0t1dF9pd1dyejZWTE4wX2hadHhJSzJ1QjJzVXljdEVHVk1SNDFnMGJHeWdDZlR0ZS1YbUc3WjRUX2tRcHVnOElLakNXYlFydTUyMlZxNVRuRl9COGQ1OWhJNEFTRzJiZElfUnlTTjZyS0x5cXFSUjRnZ1NjSVpCT003dU1jdjB0b3lReFZZczh3RFVYcEVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQb004VVV0MmJjZUNRUzdiX2RGS2FQUC1nVHlvRkNXSEo1LTRESmZkSWVQbHJZOVpBMG5DNE5NU0ZCaGR1UkQ2cXFIT2RSNGd5RzQwUTJnS045UU1iUThKeEk0dDQ2WGl4U1UtbGFWSnBMY2J4WE5CaVFrOGl6Rms2M2dSUEhHVUFuZjlsZ19iNFA0WHJHdUYzZjhWRk1xTkxBZVZrZmtSSFVBMDZt?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar raises $460M ahead of Phase 3 atopic dermatitis trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQWtHeFVkaExEdWxsZU9RQVhjVDFSQnZwY29tMjdZWXdpaVM0T3VtLWdiTFQwcnZJTHhmU0d2OXNTUVFwRWZCMmNjWkNtUnFSaUgzVGlYRnVsQnlnZnlRNkIzY3doRzd4enZSNHZZUzJSTnJDZXA1b18yX0pvMFQ0YXB2NjVFa0ZCel9QOVZCSHJsb25Ub1VrOXdkOWtENE9uNHhhVE8yQTZrX1FiNjBkak0zTkQyLXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQZ3VmZUpLOHVoSEZncXdna0pfazdzNTIxRGd2dFZJZ3RXNWY3N3ZwUzlYdGNxTW55SjhiaEZZOUw2RnNIc3NnQ2ZOdm9IMkRkSURxb1d2cVlpV19rLWhyd2tzWHVrVjNXTng2d3B0NmZiOUZfTUtCZDFxVjY5TW5iaGh2REtpQUtfbFluNHVHQ2U0cWkzaEFtQW5tZlc4ck96UmY5TEVnVHFSSlJMNE50ZlZkcnFweUt3SVNyY2Vhc3BsUExZUHRLOEdicW9jMDgx?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxOemROUE41bjFzLVdlOGVTMEdtVm96NU92R3RxVk5XNl9BcEg0VndycDhOR2xZeHUzc2lPUU92WHJkQVkyaUgwcmRYUDk0dFMwZnZJRE1QNHpuSEZrYzNOQmlWMXBneFFWX004dU9qVGF2Ymc3Z3QtLXpBR1U5T19WN1JITnY4YjhNLVB4S3B3cExQS19IZHNLdVZDcDRoTkxiWVVyUU1DTzBMYzJOeUwyZGFkTTU3VVFHUWprd1ViUVRqd3VfbEdKcGJiQW05Tm9SMVdhN1pBN01rUy1FWVpQWnNsNlZ3ejJjZURtd0IzcVJ3aHFqcjJILVM4RXE4cjR4QnEzdHZMODZHTThJcXlFR3Bpcw?oc=5", "source_name": "BioSpace", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 67, "sentiment_summary": {"positive": 18, "negative": 6, "neutral": 43, "score": 52, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 22.7, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 70.36, "latest_week": "2026-07-10", "one_week_move": -1.0, "four_week_move": 18.5, "twelve_week_move": -17.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.544229, "market_dynamics_buy_signal": false, "relative_strength": 8.102145, "fair_value_gap": 150.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.0471, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.0% over one week, +18.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 5}, {"label": "PR Newswire", "count": 5}, {"label": "ACCESS Newswire", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Stocktwits", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.0% over one week, +18.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178"}], "updated_at": "2026-07-16T07:04:04.593834+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}